Bernard MALISSEN, Chairman, is an immunologist, currently Research Director at CNRS (Marseilles/France) and formerly Director of the INSERM-CNRS Marseilles Luminy Immunology Centre (CIML). He is one of the pioneers in the field of molecular immunology in Europe and has devoted most of his working life to antigen recognition and activation of T cells, as well as to the genetics of the T receptor.
 

JAMES ALLISON is an expert in the field of antibody-mediated immune activation. He has dedicated his career to the study of how immune cells can eradicate cancer. After obtaining his Ph.D., Biological Sciences, at The University of Texas, Austin, he joined university of Berkeley, where, as professor of immunology, he discovered among many other achievements, the mechanism of action of an inhibitory T cell molecules named CTLA4, and the therapeutic potential of anti CTLA4 antibodies for cancer treatment. This discovery eventually led very recently to the registration of ipilimumab anti CTLA4 mAb, for the treatment of melanoma. Jim Allison is currently Chairman, Immunology Program at the Memorial Sloan-Kettering Cancer Center; Director, Ludwig Center of Cancer Immunotherapy; David H. Koch Chair in Immunologic Studies; Attending Immunologist, Department of Medicine; Investigator, Howard Hughes Medical Institute, where he continues to study the complex interaction between T cells and cancer cells.
 

Philip GREENBERG is a professor of medicine and immunology at the University of Washington and heads the immunology department at the Fred Hutchinson Cancer Research Center in Seattle. Philip Greenberg's laboratory focuses on studying anti-tumor T cell response and developing new cell and molecular approaches for immune intervention in oncology. He is one of the pioneers in adoptive cell immunotherapy.
 

David RAULET is a specialist in cell and molecular immunology. He has made significant contributions to the advancement of knowledge on γδ T lymphocytes and NK cells. His most recent work is related to stimulator and inhibitor receptors activated by NK cells to detect tumor cells, and the molecules corresponding to these receptors. Mr. Raulet was the head of the immunology department at the University of California at Berkeley and teaches immunology in the Department of Cell and Molecular Biology.